Publications by authors named "C A Ternent"
Purpose: The clinical efficacy of total neoadjuvant therapy (TNT) followed by selective nonoperative management (NOM) for locally advanced rectal cancer (LARC) was examined in the Organ Preservation for Rectal Adenocarcinoma (OPRA) trial. We investigated the cost and quality-of-life implications of adopting this treatment approach.
Methods: We analyzed clinical, cost, and quality-of-life outcomes for TNT with selective NOM in comparison with chemoradiotherapy (CRT)-surgery-adjuvant chemotherapy (standard of care [SOC]) using data from OPRA, prospective cohorts, and published studies.
Article Synopsis
- Assessing clinical tumor response after total neoadjuvant therapy (TNT) is crucial for determining if patients with advanced rectal cancer can undergo watch-and-wait treatment instead of surgery.
- The study analyzed outcomes related to organ preservation and survival rates based on a new three-tier grading system for tumor response (complete, near-complete, and incomplete) in a diverse group of patients.
- Results included data from 304 patients, showing that age and sex were consistent across response grades, helping inform eligibility for organ preservation strategies based on clinical outcomes.
Article Synopsis
- - The OPRA trial studied the long-term outcomes of different treatment sequences for stage II/III rectal cancer, comparing induction chemotherapy followed by chemoradiation (INCT-CRT) with chemoradiation followed by consolidation chemotherapy (CRT-CNCT) to evaluate organ preservation and oncologic results.
- - After a median follow-up of 5.1 years with 324 patients, the 5-year disease-free survival (DFS) rates were similar for both treatment groups, while TME-free survival was significantly higher in the CRT-CNCT group (54% vs. 39%).
- - The study found that most tumor regrowth occurred within the first 2 years for patients who opted for the watch-and-w
Background: Locally advanced rectal cancer has high cure rates with trimodal therapy. Studies sparing neoadjuvant chemoradiation in selected patients show comparable outcomes.
Objective: This study aimed to determine the cost-effectiveness of selective use of neoadjuvant chemoradiation in this population.